000296217 001__ 296217
000296217 005__ 20250819095640.0
000296217 0247_ $$2doi$$a10.1200/JCO-24-01441
000296217 0247_ $$2pmid$$apmid:39805062
000296217 0247_ $$2ISSN$$a0732-183X
000296217 0247_ $$2ISSN$$a1527-7755
000296217 0247_ $$2altmetric$$aaltmetric:172983007
000296217 037__ $$aDKFZ-2025-00130
000296217 041__ $$aEnglish
000296217 082__ $$a610
000296217 1001_ $$00000-0001-8860-3823$$aSchouten, Aniek E M$$b0
000296217 245__ $$aSupervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.
000296217 260__ $$aAlexandria, Va.$$bAmerican Society of Clinical Oncology$$c2025
000296217 3367_ $$2DRIVER$$aarticle
000296217 3367_ $$2DataCite$$aOutput Types/Journal article
000296217 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755590173_6399
000296217 3367_ $$2BibTeX$$aARTICLE
000296217 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000296217 3367_ $$00$$2EndNote$$aJournal Article
000296217 500__ $$a2025 Apr 10;43(11):1325-1336
000296217 520__ $$aTo evaluate the cost utility of a 9-month supervised exercise program for patients with metastatic breast cancer (mBC), compared with control (usual care, supplemented with general activity advice and an activity tracker). Evidence on the cost-effectiveness of exercise for patients with mBC is essential for implementation in clinical practice and is currently lacking.A cost-utility analysis was performed alongside the multinational PREFERABLE-EFFECT randomized controlled trial, conducted in 8 centers across Europe and Australia. Patients with mBC (N = 357) were randomly assigned to either a 9-month, twice-weekly, supervised exercise group (EG) or control group (CG). Costs of the exercise program were calculated through a bottom-up approach. Other health care resource use, productivity losses, and quality of life were collected using country-adapted, self-reported questionnaires. Analyses were conducted from a societal perspective with a time horizon of 9 months. Costs were collected and reported in 2021 Euros (€1 = $1.18 US dollars).Compared with the CG, EG resulted in a quality-adjusted life-year (QALY) gain of 0.013 (95% CI, -0.02 to 0.05) over a 9-month period. The mean costs of the exercise program were €1,696 per patient with one-on-one supervision (scenario 1) and €609 with one-on-four supervision (scenario 2). These costs were offset by savings in health care and productivity costs, resulting in mean total cost differences of -€163 (scenario 1) and -€1,249 (scenario 2) in favor of EG. The probability of supervised exercise being cost-effective was 65% in scenario 1 and 91% in scenario 2 at a willingness-to-pay threshold of €20,000 per QALY.Exercise for patients with mBC increases quality of life, decreases costs, and is likely to be cost-effective. Group-based supervision is expected to have even higher cost-savings. Our positive findings can inform reimbursement of supervised exercise interventions for patients with mBC.
000296217 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000296217 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000296217 7001_ $$00000-0002-6216-2609$$aHiensch, Anouk E$$b1
000296217 7001_ $$aFrederix, Geert W J$$b2
000296217 7001_ $$00000-0002-6641-7605$$aMonninkhof, Evelyn M$$b3
000296217 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b4$$udkfz
000296217 7001_ $$aClauss, Dorothea$$b5
000296217 7001_ $$aGunasekara, Nadira$$b6
000296217 7001_ $$aBelloso, Jon$$b7
000296217 7001_ $$00000-0002-9078-0180$$aTrevaskis, Mark$$b8
000296217 7001_ $$00000-0002-5617-9076$$aRundqvist, Helene$$b9
000296217 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b10$$udkfz
000296217 7001_ $$aMüller, Jana$$b11
000296217 7001_ $$aSweegers, Maike G$$b12
000296217 7001_ $$aFremd, Carlo$$b13
000296217 7001_ $$00000-0001-6944-5209$$aAltena, Renske$$b14
000296217 7001_ $$00000-0003-0980-6652$$aBijlsma, Rhodé M$$b15
000296217 7001_ $$00000-0001-8088-9628$$aSonke, Gabe$$b16
000296217 7001_ $$aLahuerta, Ainhara$$b17
000296217 7001_ $$00000-0002-2508-9203$$aMann, G Bruce$$b18
000296217 7001_ $$00000-0002-7207-9286$$aFrancis, Prudence A$$b19
000296217 7001_ $$00000-0003-2122-8285$$aRichardson, Gary$$b20
000296217 7001_ $$00000-0002-5693-3120$$aMalter, Wolfram$$b21
000296217 7001_ $$aKufel-Grabowska, Joanna$$b22
000296217 7001_ $$00000-0003-2568-6937$$avan der Wall, Elsken$$b23
000296217 7001_ $$00000-0003-2574-4850$$aAaronson, Neil K$$b24
000296217 7001_ $$aSenkus, Elzbieta$$b25
000296217 7001_ $$00000-0003-0359-3641$$aUrruticoechea, Ander$$b26
000296217 7001_ $$aZopf, Eva M$$b27
000296217 7001_ $$aBloch, Wilhelm$$b28
000296217 7001_ $$00000-0002-7794-7767$$aStuiver, Martijn M$$b29
000296217 7001_ $$aWengstrom, Yvonne$$b30
000296217 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b31$$udkfz
000296217 7001_ $$avan der Meulen, Miriam P$$b32
000296217 7001_ $$00000-0003-0643-3790$$aMay, Anne M$$b33
000296217 773__ $$0PERI:(DE-600)2005181-5$$a10.1200/JCO-24-01441$$gp. JCO-24-01441$$n11$$p1325-1336$$tJournal of clinical oncology$$v43$$x0732-183X$$y2025
000296217 909CO $$ooai:inrepo02.dkfz.de:296217$$pVDB
000296217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000296217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000296217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b31$$kDKFZ
000296217 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000296217 9141_ $$y2025
000296217 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-22$$wger
000296217 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ONCOL : 2022$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000296217 915__ $$0StatID:(DE-HGF)9940$$2StatID$$aIF >= 40$$bJ CLIN ONCOL : 2022$$d2023-10-22
000296217 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Krebsprävention und Survivorship$$x0
000296217 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x1
000296217 980__ $$ajournal
000296217 980__ $$aVDB
000296217 980__ $$aI:(DE-He78)C110-20160331
000296217 980__ $$aI:(DE-He78)D120-20160331
000296217 980__ $$aUNRESTRICTED